This site is intended for healthcare professionals
News

EMA accepts for review MAA for aducanumab treatment for mild Alzheimer’s disease. Eisai + Biogen.

Read time: 1 mins
Last updated:31th Oct 2020
Published:31th Oct 2020
Condition: Alzheimers
Type: drug
Register free for full access to medthority.com